drugset / Trial / NCT04158336
A Study of Azenosertib (ZN-c3) in Participants With Solid Tumors
Phase 1
Completed
274 enrolled
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
RandomizedParallel-groupOpen-labelTreatment
Summary
This is a Phase 1 open-label, multicenter study of ZN-c3 (also known as Azenosertib) monotherapy which consists of Dose Escalation, a Food Effect Cohort, and Dose Expansion.
Timeline
- Start
- 2019-11-01
- Primary completion
- 2025-05-06
- Completion
- 2025-05-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Azenosertib | Small molecule | — | — |